Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Executive Summary

• Lobe Sciences reported FY2025 audited results, showing a cash balance of $5.85 M and working‑capital surplus of $5.16 M after significant balance‑sheet restructuring.
• The company completed an $8.46 M financing at its 64%‑owned subsidiary Cynaptec Pharmaceuticals, preserving shareholder participation while funding the L‑130 program.
• Management highlighted progress on two core programs (L‑130 for chronic cluster headache and S‑100 for sickle cell disease) and outlined a strategic outlook for FY2026 focused on further infrastructure strengthening and value‑accretive opportunities.

Key Details

• Cash Position: $5,854,118 as of Aug 31 2025 (up from $237,772 on Aug 31 2024).
• Short‑Term Investments: $1,686,688 held at FY end 2025 (none reported in FY 2024).
• Working Capital: Surplus of $5,163,526 versus a deficit of $2,008,849 one year earlier.
• Convertible Notes (current portion): Reduced to $0 from $641,374.
• Derivative Liability: Decreased to $205,105 from $603,724.
• Net Loss (attributable to parent): $4,861,611 for FY 2025 (FY 2024: $4,420,727).
• Loss per Share: $0.03 (FY 2024: $0.04).

Financing at Subsidiary Level

• Entity: Cynaptec Pharmaceuticals, Inc. (64% owned by Lobe).
• Amount Raised: $8,460,000.
• Post‑Money Valuation: $22,560,000.
• Ownership Retained: 64% for Lobe Sciences.

Program Updates

• Cynaptec – L‑130 (psilocin mucate): Completed Phase 1a in healthy volunteers; preclinical work finished; advancing under FDA Pre‑IND guidance for chronic cluster headache and exploring substance‑use disorder indications.
• Altemia – S‑100: Early‑stage candidate for sickle cell disease; focus sharpened on lipid‑based delivery platform (DHA/EPA triglycerides with surfactants).
• Medical Food Initiative: Preliminary commercialization activities targeting reimbursement for nutritional deficiencies in sickle‑cell patients; future viability uncertain.

Strategic Outlook FY2026

• Continue strengthening corporate infrastructure and liquidity.
• Advance core development programs through disciplined milestone execution.
• Evaluate strategic transactions, financing alternatives, and other value‑creation opportunities (subject to market, regulatory, and financing conditions).

Notable Quotes

“During fiscal 2025, our focus was on strengthening the Company's financial position, reducing legacy liabilities, and ensuring that our core assets were funded in a manner that preserved long-term shareholder participation.” – Dr. Frederick D. Sancilio, Chairman & CEO

Materiality Assessment: Material – Positive (significant balance‑sheet improvement, sizable subsidiary financing, and strategic program progress).